This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Optical Detection of Malignancy During Percutaneous Interventions

This study has been completed.
Information provided by (Responsible Party):
Philips Healthcare Identifier:
First received: October 4, 2012
Last updated: April 8, 2016
Last verified: April 2016
Investigation of application possibilities of optical spectroscopy within the field of oncology. Optical spectroscopy enables the possibility to specifically differentiate between different (human) tissues. The hypothesis is that incorporation of this technique into existing medical devices (e.g. biopsy needle) would enlarge the accuracy and reliability of these devices. The purpose is to improve and speed up the diagnostics and therapy of the malignancies.

Condition Intervention
Pulmonary Coin Lesion Colon Cancer Liver Metastasis Breast Cancer Procedure: Core biopsy procedure

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Discrimination of Benign and Malignant Human Tissue During Percutaneous Interventions Using Optical Spectroscopy Techniques

Resource links provided by NLM:

Further study details as provided by Philips Healthcare:

Primary Outcome Measures:
  • Differentiation between normal and malignant tissue [ Time Frame: Day 0 ]
    Statistical analysis of the difference between diffuse reflectance spectra obtained at normal and malignant measurement locations

Biospecimen Retention:   Samples Without DNA
Biopsies are taken from the enrolled patients and these biopsies are send to the pathology department for histopathological analysis.

Enrollment: 104
Study Start Date: October 2012
Study Completion Date: December 2015
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Histological biopsy procedures
Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis
Procedure: Core biopsy procedure
Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
Other Names:
  • Histological biopsy procedure
  • Standard biopsy procedure

Detailed Description:

Primary Objective:

In this observational study the investigators aim to evaluate whether optical spectroscopy can correctly diagnose malignant tissue in the existing clinical workflow of percutaneous interventions in lung, liver, and breast.

Secondary Objective:

During the measurement procedure, possible improvements of the measurement hardware will be recorded. Analysis of this documentation will provide information for possible alterations of hardware design for improved clinical applicability in the future. Special attention will be paid to observe how the procedure fits in the standard workflow of the radiologist.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Eligible patients are all patients, who are scheduled for a standard core biopsy of lung, liver or breast; or percutaneous RFA of liver in the Netherlands Cancer Institute (NKI-AvL), Amsterdam, The Netherlands. In the enrollment process the "patient informatie" will be used and the informed consent must be signed prior to the intervention.

Inclusion Criteria:

  • Patients with a suspicious lesion in lung or liver who are scheduled for a standard core biopsy procedure
  • Patient planned for percutaneous RFA of colorectal liver metastasis
  • Written informed consent
  • Patients ≥ 18 years old
  • Breast patients with a BIRADS score 4 or 5

General Exclusion criteria:

  • Patients who have higher risk of bleeding
  • Patients with suspected sensitivity to light; e.g. patients who have had photodynamic therapy

Breast Specific Exclusion criteria:

  • Patients who have a history of breast cancer and/or who have received prior chemotherapy, endocrine therapy, or radiation therapy
  • Patients who have breast implants
  • Patients needing a stereotactic breast biopsy (i.e. non palpable-, ultrasound opaque lesions)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01730365

Nederlands Kanker Instituut/Antonie van Leeuwenhoek Ziekenhuis
Amsterdam, Noord-Holland, Netherlands, 1066 CX
Sponsors and Collaborators
Philips Healthcare
Principal Investigator: Theo Ruers, MD Nederlands Kanker Instituut/Antonie van leeuwenhoek Ziekenhuis
  More Information

Responsible Party: Philips Healthcare Identifier: NCT01730365     History of Changes
Other Study ID Numbers: NL40578.031.12
Study First Received: October 4, 2012
Last Updated: April 8, 2016

Keywords provided by Philips Healthcare:

Additional relevant MeSH terms:
Solitary Pulmonary Nodule
Lung Diseases
Respiratory Tract Diseases processed this record on August 23, 2017